Study S001368

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus: Sema-Lit

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06060392
Acronym: Sema-Lit
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Masking: NONE
Status: RECRUITING
Enrollment: 50
Start: 2023-10-30
Primary completion: 2025-09-02
Lead sponsor: Medanta, The Medicity, India
Conditions: Liver Transplant; Complications; Diabete Mellitus
Interventions: DRUG:Semaglutide Pill
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in liver fat content [Baseline to 24 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011197	Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Alkhouri N, Journal of hepatology	2022	Randomized trial	PMID 35439567 DOI	registry reference RESULT:35439567
R0012449	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. Newsome PN, The New England journal of medicine	2021	Randomized trial	PMID 33185364 DOI	registry reference RESULT:33185364